Literature DB >> 19549778

Structural and functional alterations of FLT3 in acute myeloid leukemia.

Soheil Meshinchi1, Frederick R Appelbaum.   

Abstract

Hematopoiesis is highly regulated through cytokine-induced stimulation of multiple signal transduction pathways in order to mediate appropriate differentiation and proliferation of specific progenitor populations. Ligand-induced stimulation of the FMS-like tyrosine kinase 3 (FLT3) leads to activation of multiple downstream effector pathways resulting in differentiation and proliferation of specific progenitor cell populations. Genomic alterations of the FLT3 gene, including FLT3 internal tandem duplication (FLT3/ITD) and FLT3 activation loop mutation (FLT3/ALM) lead to autonomous receptor activation, dysregulation of FLT3 signal transduction pathways, contribute to myeloid pathogenesis, and have been linked to response to therapy and clinical outcome. Exploring the mechanisms by which these FLT3 alterations lead to dysregulated proliferation should provide a better understanding of the molecular pathogenesis of acute myeloid leukemia (AML) and may provide insights into potential therapeutic interventions. FLT3 inhibitors are under evaluation for their efficacy in AML patients with FLT3 mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549778      PMCID: PMC2716016          DOI: 10.1158/1078-0432.CCR-08-1123

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  73 in total

1.  Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.

Authors:  F M Abu-Duhier; A C Goodeve; G A Wilson; R S Care; I R Peake; J T Reilly
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

2.  Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.

Authors:  Sridhar Vempati; Carola Reindl; Seshu Kumar Kaza; Ruth Kern; Theodora Malamoussi; Martin Dugas; Gudrun Mellert; Susanne Schnittger; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2007-03-26       Impact factor: 22.113

3.  Clinical implications of FLT3 mutations in pediatric AML.

Authors:  Soheil Meshinchi; Todd A Alonzo; Derek L Stirewalt; Michel Zwaan; Martin Zimmerman; Dirk Reinhardt; Gertjan J L Kaspers; Nyla A Heerema; Robert Gerbing; Beverly J Lange; Jerald P Radich
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

4.  Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.

Authors:  Pei Lin; Dan Jones; L Jeffrey Medeiros; Weina Chen; Francisco Vega-Vazquez; Rajyalakshmi Luthra
Journal:  Am J Clin Pathol       Date:  2006-10       Impact factor: 2.493

5.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

6.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.

Authors:  Lukasz P Gondek; Ramon Tiu; Christine L O'Keefe; Mikkael A Sekeres; Karl S Theil; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2007-10-22       Impact factor: 22.113

7.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

8.  Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia.

Authors:  Manoj Raghavan; Lan-Lan Smith; Debra M Lillington; Tracy Chaplin; Ioannis Kakkas; Gael Molloy; Claude Chelala; Jean-Baptiste Cazier; James D Cavenagh; Jude Fitzgibbon; T Andrew Lister; Bryan D Young
Journal:  Blood       Date:  2008-05-19       Impact factor: 22.113

9.  Structural and numerical variation of FLT3/ITD in pediatric AML.

Authors:  Soheil Meshinchi; Derek L Stirewalt; Todd A Alonzo; Titus J Boggon; Robert B Gerbing; Jennifer L Rocnik; Beverly J Lange; D Gary Gilliland; Jerald P Radich
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

10.  FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

Authors:  Adam J Mead; David C Linch; Robert K Hills; Keith Wheatley; Alan K Burnett; Rosemary E Gale
Journal:  Blood       Date:  2007-04-24       Impact factor: 22.113

View more
  82 in total

1.  Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia.

Authors:  Amy L Paguirigan; Jordan Smith; Soheil Meshinchi; Martin Carroll; Carlo Maley; Jerald P Radich
Journal:  Sci Transl Med       Date:  2015-04-01       Impact factor: 17.956

2.  Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Authors:  Aref Al-Kali; Jorge Cortes; Stefan Faderl; Dan Jones; Caroline Abril; Sherry Pierce; Mark Brandt; Hagop Kantarjian; Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

3.  Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.

Authors:  Xiaomu Wei; Todd D Prickett; Cristina G Viloria; Alfredo Molinolo; Jimmy C Lin; Isabel Cardenas-Navia; Pedro Cruz; Steven A Rosenberg; Michael A Davies; Jeffrey E Gershenwald; Carlos López-Otín; Yardena Samuels
Journal:  Mol Cancer Res       Date:  2010-10-13       Impact factor: 5.852

4.  Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.

Authors:  Angeliki Thanasopoulou; Alexandar Tzankov; Juerg Schwaller
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

5.  Leukemia Inhibitory Factor Inhibits Plasmacytoid Dendritic Cell Function and Development.

Authors:  Renata Sesti-Costa; Luisa Cervantes-Barragan; Melissa K Swiecki; José Luís Fachi; Marina Cella; Susan Gilfillan; João Santana Silva; Marco Colonna
Journal:  J Immunol       Date:  2020-03-13       Impact factor: 5.422

6.  FLT3-ITD gets by with a little help from PRMT1.

Authors:  Kira Gritsman
Journal:  Blood       Date:  2019-08-08       Impact factor: 22.113

7.  Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.

Authors:  Stephen T Keir; John M Maris; Richard Lock; E Anders Kolb; Richard Gorlick; Hernan Carol; Christopher L Morton; C Patrick Reynolds; Min H Kang; Amy Watkins; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

8.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

9.  Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.

Authors:  Singkome Tima; Siriporn Okonogi; Chadarat Ampasavate; Chad Pickens; Cory Berkland; Songyot Anuchapreeda
Journal:  J Pharm Sci       Date:  2016-10-14       Impact factor: 3.534

10.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.